ACAD Valuation

ACADIA Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

23.050

-0.22(-0.945%)1D

Overview
Forecast
Valuation
Earnings

ACAD Relative Valuation

ACAD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ACAD is overvalued; if below, it's undervalued.

Historical Valuation

ACADIA Pharmaceuticals Inc (ACAD) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.43 is considered Undervalued compared with the five-year average of -12.61. The fair price of ACADIA Pharmaceuticals Inc (ACAD) is between 657.07 to 695.94 according to relative valuation methord. Compared to the current price of 23.27 USD , ACADIA Pharmaceuticals Inc is Undervalued By 96.46%.

Relative Value

Fair Zone

657.07-695.94

Current Price：23.27

96.46%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

5.08

P/B

Median3y

7.12

Median5y

7.44

3.93

FCF Yield

Median3y

0.54

Median5y

-1.10

Competitors Valuation Multiple

The average P/S ratio for ACAD's competitors is 6.56, providing a benchmark for relative valuation. ACADIA Pharmaceuticals Inc Corp (ACAD) exhibits a P/S ratio of 3.47, which is -47.04% above the industry average. Given its robust revenue growth of 18.70%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ACAD.O

ACADIA Pharmaceuticals Inc

3.47

Average P/S: 6.56

18.70%